About Haemonetics Corporation
Ticker
info
HAE
Trading on
info
NYSE
ISIN
info
US4050241003
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
Christopher A. Simon
Headquarters
info
125 Summer Street, Boston, MA, United States, 02110
Employees
info
3,023
Website
info
haemonetics.com
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$4.04B
P/E ratio
info
24.51
EPS
info
$3.42
Dividend Yield
info
0.00%
Beta
info
0.36
Forward P/E ratio
info
15.04
EBIDTA
info
$360M
Ex dividend date
info
-
Price & volume
Market cap
info
$4.04B
Average daily volume
info
1.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
24.51
Forward P/E
info
15.04
PEG ratio
info
1.25
Trailing P/E
info
24.51
Price to sales
info
3.04
Price to book
info
4.52
Earnings
EPS
info
$3.42
EPS estimate (current quarter)
info
$1.11
EPS estimate (next quarter)
info
$1.27
EBITDA
info
$360M
Revenues (TTM)
info
$1.33B
Revenues per share (TTM)
info
$27.21
Technicals
Beta
info
0.36
52-week High
info
$85.23
52-week Low
info
$47.32
50-day moving average
info
$59.78
200-day moving average
info
$63.51
Short ratio
info
3
Short %
info
8.58%
Management effectiveness
ROE (TTM)
info
19.47%
ROA (TTM)
info
6.36%
Profit margin
info
12.67%
Gross profit margin
info
$790M
Operating margin
info
21.02%
Growth
Quarterly earnings growth (YoY)
info
22.70%
Quarterly revenue growth (YoY)
info
-5.30%
Share stats
Outstanding Shares
info
46.8M
Float
info
46.2M
Insiders %
info
1.18%
Institutions %
info
113.52%
Analyst Insights & forecasts
info

80% Buy

10% Hold

10% Sell

Based on information from 10 analysts.

Average price target

info
$84.55
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.74
$0.91
-18.68%
Q4 • 24Missed
$1.24
$1.22
1.64%
Q1 • 25Beat
$1.10
$1.02
7.84%
Q2 • 25Beat
$1.27
$1.11
14.41%
Q3 • 25Beat
-
$1.25
-
Q4 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$321M
$34M
10.59%
Q2 • 25
$327M
$38.7M
11.82%
Q3 • 25
1.84%
13.67%
11.62%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$2.46B
$1.58B
64.16%
Q2 • 25
$2.44B
$1.59B
65.23%
Q3 • 25
-0.81%
0.83%
1.66%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$17.4M
$-33M
$-2.4M
$13.6M
Q2 • 25
$111M
$-30.5M
$-76.6M
$106M
Q3 • 25
539.96%
-7.67%
3,034.81%
679.31%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Haemonetics Corporation share?
Collapse

Haemonetics Corporation shares are currently traded for undefined per share.

How many shares does Haemonetics Corporation have?
Collapse

Haemonetics Corporation currently has 46.8M shares.

Does Haemonetics Corporation pay dividends?
Collapse

No, Haemonetics Corporation doesn't pay dividends.

What is Haemonetics Corporation 52 week high?
Collapse

Haemonetics Corporation 52 week high is $85.23.

What is Haemonetics Corporation 52 week low?
Collapse

Haemonetics Corporation 52 week low is $47.32.

What is the 200-day moving average of Haemonetics Corporation?
Collapse

Haemonetics Corporation 200-day moving average is $63.51.

Who is Haemonetics Corporation CEO?
Collapse

The CEO of Haemonetics Corporation is Christopher A. Simon.

How many employees Haemonetics Corporation has?
Collapse

Haemonetics Corporation has 3,023 employees.

What is the market cap of Haemonetics Corporation?
Collapse

The market cap of Haemonetics Corporation is $4.04B.

What is the P/E of Haemonetics Corporation?
Collapse

The current P/E of Haemonetics Corporation is 24.51.

What is the EPS of Haemonetics Corporation?
Collapse

The EPS of Haemonetics Corporation is $3.42.

What is the PEG Ratio of Haemonetics Corporation?
Collapse

The PEG Ratio of Haemonetics Corporation is 1.25.

What do analysts say about Haemonetics Corporation?
Collapse

According to the analysts Haemonetics Corporation is considered a buy.